International Clinical Trial: An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barre Syndrome (FORWARD Study)

Geneva, June 20 -- International Clinical Trials Registry received information related to the study (NCT07020819) titled 'An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barre Syndrome (FORWARD Study)' on June 6.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Annexon, Inc.

Condition: Guillain-Barre Syndrome

Intervention: Drug: Tanruprubart

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: June 2025

Target Sample Size: 30

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07020819

Disclaimer: Cu...